Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Clinical trial NCT02359565 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02359565
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Constitutional Mismatch Repair Deficiency Syndrome Lynch Syndrome Malignant Glioma Recurrent Brain Neoplasm Recurrent Childhood Ependymoma Recurrent Diffuse Intrinsic Pontine Glioma Recurrent Medulloblastoma Refractory Brain Neoplasm Refractory Diffuse Intrinsic Pontine Glioma Refractory Ependymoma Refractory Medulloblastoma

Start date: 2015-06-03
Primary completion: 2026-01-05
Enrollment: 71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.